| Recruiting | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial NCT07015892 | Instituto de Investigación Biomédica de Salamanca | Phase 3 |
| Not Yet Recruiting | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD NCT07357532 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) NCT07155200 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Recruiting | MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients NCT07509333 | West China Hospital | N/A |
| Recruiting | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. NCT06992609 | AstraZeneca | Phase 3 |
| Recruiting | A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 | Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chin NCT06799286 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | A Study of Hospital-at-Home for People Receiving Tarlatamab NCT06957314 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients NCT06481813 | Nantes University Hospital | N/A |
| Enrolling By Invitation | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cispla NCT06419179 | University of Cologne | Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Completed | REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER NCT06826677 | AstraZeneca | — |
| Not Yet Recruiting | An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy NCT06501976 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer NCT06529081 | Copernicus Memorial Hospital | N/A |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | PET-guided Radiotherapy for Patients With Small Cell Lung Cancer. NCT06247163 | University Hospital, Essen | — |
| Not Yet Recruiting | Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cance NCT06236997 | Henan Cancer Hospital | Phase 2 |
| Recruiting | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-S NCT06177925 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | A Phase IIII Study of AL8326 in Small Cell Lung Cancer NCT06247605 | Advenchen Laboratories Nanjing Ltd. | Phase 3 |
| Recruiting | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Oth NCT05882058 | Boehringer Ingelheim | Phase 2 |
| Recruiting | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer NCT05620342 | UNC Lineberger Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cance NCT05582031 | Translational Research in Oncology | Phase 2 |
| Active Not Recruiting | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small C NCT05616624 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Recruiting | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease NCT05617963 | UNICANCER | Phase 2 |
| Terminated | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolat NCT05049863 | Washington University School of Medicine | Phase 1 |
| Recruiting | Biology of Young Lung Cancer Study: The YOUNG LUNG Study NCT05265429 | Dana-Farber Cancer Institute | — |
| Not Yet Recruiting | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy NCT05703997 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Active Not Recruiting | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stag NCT05683977 | AstraZeneca | — |
| Recruiting | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer NCT05450965 | University of Maryland, Baltimore | Phase 2 |
| Recruiting | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain NCT05419076 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to NCT05329623 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment NCT05224141 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer NCT05027867 | Kartos Therapeutics, Inc. | Phase 2 |
| Unknown | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer NCT04996771 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-34 NCT04938817 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Unknown | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer NCT04901754 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-i NCT06558903 | University Hospital, Brest | — |
| Active Not Recruiting | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04902872 | Cybrexa Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreate NCT04665856 | Hoffmann-La Roche | Phase 3 |
| Completed | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Ver NCT04672928 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy NCT04620837 | Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Terminated | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC NCT03963414 | University of Nebraska | Phase 1 |
| Completed | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. NCT04358237 | Antonio Calles Blanco | Phase 1 / Phase 2 |
| Unknown | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apa NCT04453930 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC NCT04363255 | Taizhou Hospital | Phase 2 |
| Terminated | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced L NCT03735095 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer NCT04173325 | Augusta University | Phase 1 |
| Recruiting | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 NCT04199741 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC NCT03994744 | Hunan Cancer Hospital | Phase 2 |
| Completed | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in P NCT04028050 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and NCT03850067 | Celgene | Phase 1 |
| Unknown | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC NCT03700359 | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Terminated | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer NCT03662074 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer NCT03568097 | Hellenic Cooperative Oncology Group | Phase 2 |
| Completed | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer NCT03532880 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Unknown | A Mobile Supportive Care App for Patients With Metastatic Lung Cancer NCT03512015 | Bocconi University | N/A |
| Completed | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors NCT03509012 | AstraZeneca | Phase 1 |
| Terminated | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors NCT02937402 | Vanderbilt-Ingram Cancer Center | N/A |
| Active Not Recruiting | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung C NCT03319940 | Amgen | Phase 1 |
| Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) NCT03232593 | Hoffmann-La Roche | — |
| Withdrawn | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarci NCT02876081 | Fondation Hôpital Saint-Joseph | Phase 2 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of AK-01 (LY3295668) in Solid Tumors NCT03092934 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lun NCT02874664 | Stemcentrx | Phase 1 |
| Completed | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-St NCT02763579 | Hoffmann-La Roche | Phase 3 |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Recruiting | Molecular Analysis and Treatment Options of SCLC NCT05945745 | Shanghai Chest Hospital | — |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Smal NCT02487095 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer NCT02394548 | Massachusetts General Hospital | N/A |
| Completed | Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) NCT02397733 | Grupo de Investigación Clínica en Oncología Radioterapia | N/A |
| Terminated | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer NCT02161419 | Bayer | Phase 2 |
| Active Not Recruiting | Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer NCT02041845 | Norwegian University of Science and Technology | N/A |
| Terminated | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy NCT02062632 | Mayo Clinic | Phase 2 |
| Completed | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients NCT01941316 | Cancer Research and Biostatistics Clinical Trials Consortium | Phase 1 / Phase 2 |
| Unknown | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer NCT01977235 | Third Military Medical University | Phase 2 |
| Terminated | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and NCT01573338 | Bayer | Phase 1 / Phase 2 |
| Terminated | A Study of LY2940680 in Small Cell Lung Cancer NCT01722292 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the NCT01553916 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and P NCT01450761 | Bristol-Myers Squibb | Phase 3 |
| Unknown | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lun NCT01441349 | National Cancer Center, Korea | Phase 2 |
| Completed | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lu NCT01357395 | Astex Pharmaceuticals, Inc. | Phase 2 |
| Completed | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors NCT01286987 | Pfizer | Phase 1 |
| Completed | Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer NCT01540045 | Instituto Nacional de Cancerologia de Mexico | — |
| Terminated | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network NCT01574300 | Addario Lung Cancer Medical Institute | — |
| Terminated | Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplati NCT01187615 | Bayer | Phase 1 |
| Terminated | A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With NCT00977561 | Pfizer | Phase 2 |
| Completed | A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-S NCT00927875 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carci NCT00926640 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory NCT00759824 | European Lung Cancer Working Party | Phase 2 |
| Completed | LBH Phase II in Small Cell Lung Cancer (SCLC) NCT01222936 | Southern Europe New Drug Organization | Phase 2 |
| Completed | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malign NCT00445198 | AbbVie (prior sponsor, Abbott) | Phase 1 / Phase 2 |
| Completed | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced C NCT00423254 | Mannkind Corporation | Phase 1 |
| Terminated | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer NCT00299390 | Bayer | Phase 2 |
| Completed | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung NCT00143455 | Pfizer | Phase 3 |
| Available | Oral Green Tea Extract for Small Cell Lung Cancer NCT01317953 | Shandong Cancer Hospital and Institute | — |
| No Longer Available | Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Comb NCT04507919 | Novartis Pharmaceuticals | — |